stsp-0902
Small moleculeexperimental
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 31, 2024 (NCT06563713)
Timeline
Indications
Mechanism of action
NTRK1 agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06975748 | Phase 2 | Jun 12, 2025 | Staidson (Beijing) Biopharmaceuticals Co., Ltd |
| NCT06948799 | Phase 1 | May 8, 2025 | Peking University, Staidson (Beijing) Biopharmaceuticals Co., Ltd |
| NCT06597422 | Phase 1 | Oct 31, 2024 | Capital Medical University, Staidson (Beijing) Biopharmaceuticals Co., Ltd |
| NCT06563713 | Phase 1 | Jul 31, 2024 | Peking University, Staidson (Beijing) Biopharmaceuticals Co., Ltd |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Staidson (Beijing) Biopharmaceuticals Co., Ltd | For profit | 4 | 4 | 2 | 2024 |
| Peking University | Academic/Hospital | 2 | 0 | 1 | 2024 |
| Capital Medical University | Academic/Hospital | 1 | 0 | 1 | 2024 |
3 organizations
Page 1 / 1